📰 Andreaf Wainer News
Page 6 - Andreaf Wainer News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Andreaf Wainer. Real-time updates on events, politics, business and more.
April 28, 2024
Sector Gamma AS acquired a new stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 39,876 shares of the healthcare product maker’s stock, valued at approximately $4,389,000. Abbott Laboratories makes up 1.1% of Sector […]
April 28, 2024
IMA Wealth Inc. trimmed its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 10.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,152 shares of the healthcare product maker’s stock after selling 250 shares during the […]
April 28, 2024
Cornerstone Capital Inc. reduced its position in Abbott Laboratories (NYSE:ABT – Free Report) by 4.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 241,640 shares of the healthcare product maker’s stock after selling 11,176 shares during the period. Abbott […]
April 28, 2024
Sargent Investment Group LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 4.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,640 shares of the healthcare product maker’s stock after selling 445 shares during the quarter. Sargent […]
April 27, 2024
Truist Financial Corp trimmed its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 3.3% in the 4th quarter, HoldingsChannel reports. The firm owned 2,839,281 shares of the healthcare product maker’s stock after selling 96,735 shares during the quarter. Truist Financial Corp’s holdings in Abbott Laboratories were worth $312,520,000 at the end of the most […]
April 27, 2024
Raymond James reiterated their buy rating on shares of Abbott Laboratories (NYSE:ABT – Free Report) in a report released on Wednesday morning, Stock Target Advisor reports. They currently have a $124.00 price objective on the healthcare product maker’s stock. Several other equities analysts have also weighed in on the stock. Royal Bank of Canada cut […]
April 27, 2024
WD Rutherford LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 1.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 10,968 shares of the healthcare product maker’s stock after selling 215 shares during the period. WD Rutherford LLC’s holdings in Abbott Laboratories were worth $1,252,000 as of […]
April 27, 2024
Overbrook Management Corp increased its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 13.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 7,804 shares of the healthcare product maker’s stock after acquiring an additional 900 shares during the period. Overbrook Management […]
April 27, 2024
Overbrook Management Corp increased its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 13.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,804 shares of the healthcare product maker’s stock after purchasing an additional 900 shares during the period. Overbrook Management […]
April 27, 2024
O Brien Greene & Co. Inc cut its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 1.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,689 shares of the healthcare product maker’s stock after selling 125 shares during the period. […]